Check here weekly for the latest news in the healthcare media and POC marketing space.

Featuring >> The Food and Drug Administration on Thursday approved Brineura as a treatment
for a specific form of Batten disease. BioMarin Pharmaceuticals’ Brineura is the first FDA-approved treatment to slow loss of walking ability...

 

Featuring >> One of the biggest content marketing trends in 2016 was the use of Facebook Live videos. Brands across sectors used this channel to provide audiences with interesting and valuable content. Surprisingly, use of this innovative video format even included pharmaceutical brands, which traditionally have been cautious about their social media presence...

 

Featuring >> When it comes to drug launches, who doesn’t love to gaze into a crystal ball? Here at FiercePharmaMarketing, we featured some of those numbers in a special report this February...

 

Featuring >> Israel-based Teva Pharmaceutical Industries Ltd said the U.S. Food and Drug
Administration had approved its drug to treat chorea stemming from Huntington's disease,
a fatal degenerative disorder...

 

Featuring >> Pharma marketers continued to up their social media game in 2016, according
to a new report, with many embracing disease awareness and charitable causes to drive engagement across social networks...

 

Featuring >> Several companies in the medical marketing space are aiming to simplify the website
log-in process for physicians — or bypass it entirely — in response to doctors' tendencies to overlook
online medical content in favor of sites like Wikipedia...

 

Featuring >> Wearable tech is increasingly making its way into pharma, and Takeda is welcoming
the trend with open arms. Most recently, the Japanese drugmaker partnered with digital health tools venture Cognition Kit to collect active and passive patient data for a deep dive on depression...

 

Featuring >> The needs and desires of today’s, digital consumers are quickly reshaping
how we need to communicate with and meet the needs of patients...

 

Featuring >> After an unusually slow year for new drug approvals—the FDA greenlighted just
22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017.
One thing’s for sure, though: No matter what total the industry tallies up this year, the crop
will bring some would-be blockbusters and market disrupters...

 

Featuring >> The Food and Drug Administration has approved Allergan’s Rhofade (oxymetazoline hydrochloride) cream, the company announced Thursday. The cream is indicated to treat persistent facial redness from rosacea in adults...

 

Featuring >> CVS introduced a generic version of injectable epinephrine to compete with
Mylan’s EpiPen at all of its locations. The product carries a cash price of $109.99 for a two-pack...

 

Featuring >> Despite the proliferation of health and wellness information online and in real life, according to the National Center for Education Statistics, only 12% of the U.S. adult population is “health literate.” Many people do not possess the necessary information to be proactive about managing their own health, an issue that can be offset by providing content that empowers decision-making and motivates positive action...

 

Featuring >> Allergan’s planning to keep the label expansions coming for blockbuster Botox,
which already boasts a range of indications in both the therapeutic and aesthetic spheres.
And the company is eyeing depression as the product’s next frontier...

 

Featuring >> Pfizer launched its own health app in September, Moodivator, a mood tracking app for depression sufferers. The app is part of a support and motivation system created around the pharma company's depression drug Pristiq...

 

Featuring >> Even though physicians are spending more time using electronic health records, drugmakers need to make sure they are providing the right information at the right time, according a pharmaceutical executive at Eli Lilly...

 

Featuring >> Eli Lilly got a big boost for its diabetes drug franchise on Friday when the FDA approved its SGLT2 diabetes drug Jardiance to reduce the risk of cardiovascular death in adult patients with Type 2 diabetes and cardiovascular disease...

 

Featuring >> Depending on whom you ask, the doctor–patient dialogue is either as productive
as it's ever been or broken beyond easy repair...

 

Featuring >> How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information. Compared to even five years ago, the occurrence
of face-to-face doctor–pharma rep meetings has fallen as doctors steadily look to iPads, tablets, and smartphones to stay current with changing trends...

 

Featuring >> Sunovion Pharmaceuticals Inc. and Cynapsus Therapeutics Inc. today announced that the companies have signed a definitive agreement under which Sunovion will acquire Cynapsus...

 

Featuring >> How much attention do people pay to the risk information for prescription drugs?
If you said “not much,” you would be correct. A recent study found that, while about 80 percent
of those viewing risk information for a fictitious allergy drug claimed to have read at least
half or more of the warnings, an eye-tracking tool found they actually read little to none of
the cautionary material on a product website...

 

Featuring >> Will one plus one equal three for Sanofi and Verily’s new venture Onduo? That’s the plan for the announced diabetes deal, the latest pharma and tech joint venture in the emerging Internet of Medical Things space...

 

Featuring >> The world’s largest CRO and one of the biggest healthcare data and consulting
firms have become one major $19 billion 50,000-strong company this week as QuintilesIMS
comes into life...

 

Featuring >> The FDA approved Amgen's Amjevita — the first biosimilar of AbbVie's best-selling inflammatory drug Humira. Amjevita is the fourth biosimilar approved in the U.S...

 

Featuring >> Pfizer has launched a new mobile app for patients suffering from depression
that it hopes will enable them to take a more active role in managing their condition...

 

Featuring >> US regulators have cleared a Bluetooth-enabled insulin pen and associated smartphone app from Companion Medical...

 

Featuring >> Scientists are developing dust-sized wireless sensors implanted inside the
body to track neural activity in real-time, offering a potential new way to monitor or treat
a range of conditions including epilepsy and control next-generation prosthetics...

 

Featuring >> Amgen notched up data for a new Prolia use that could amp up the
blockbuster-in-the-making. In a late-stage trial, Prolia beat Allergan’s Actonel at building bone density in the hip and spine in patients who suffer from glucocorticoid-induced osteoporosis...

 

Featuring >> Rainbow Light on Wednesday added two new formulations to its prenatal suite:
35+ Mom & Baby, a one-per-day prenatal multivitamin specifically formulated for expectant mothers over 35, and Prenatal & Postnatal Protein, a supplement designed to provide sustained energy from conception through nursing...

 

Featuring >> When Sanofi dumped the inhaled insulin Afrezza back on its developer MannKind earlier this year, the smaller company hailed it as an opportunity. Afrezza was just one product
in the BIg Pharma’s diabetes family. It would never have Sanofi’s undivided attention. Back home at MannKind, it would be an only child...

 

Featuring >> When it comes to online retailing, said a Walgreens executive, the way to win with digital is by narrowing your strategy, not broadening it...

 

Featuring >> GSK Consumer Healthcare on Wednesday unveiled the next big switch that
will hit allergy aisles in 2017 - the U.S. Food and Drug Administration approved the company's Flonase Sensimist Allergy Relief as an over-the-counter treatment for symptoms associated
with seasonal and perennial allergies...

 

Featuring >> Makers of inhalers to treat asthma and chronic lung disease are racing to
develop a new generation of smart devices with sensors to monitor if patients are using
their puffers properly...

 

Featuring >> Clarion Brands, a portfolio company of Swander Pace Capital, on Tuesday
announced the acquisition of the probiotic brand Florajen...

 

Featuring >> Shire has won U.S. approval for its most important new medicine, a treatment for dry eyes, in a fresh boost for the company which completed its $32 billion acquisition of U.S. rare diseases specialist Baxalta last month....

 

Featuring >> Drugmaker Merck & Co., and Premier, the GPO and performance improvement company, are teaming up to develop app-based solutions to assist providers in improving
their population health outcomes...

 

Featuring >> Celgene has formed an academic research consortium to develop innovative
new cancer therapeutics and diagnostics. The company will collaborate with four National
Cancer Institute centers in the US over the next ten years to hasten the delivery of disease-
altering programs...

 

Featuring >> By 2020 the current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model as the industry shifts from a mass-market to a
target-market approach to increase revenue...

Featuring >> Pharma is ramping up investment in patient services but is struggling to measure
the impact of services on outcomes. Pharma companies are set to invest heavily by 2018 in initiatives such as medication delivery, treatment adherence and remote monitoring in order
to help patients, according to an Accenture report...

Featuring >> Faced with a scarcity of tumor samples, a pair of top cancer institutes went directly
to patients to recruit research participants—and it worked...

Featuring >> The American Diabetes Association on Tuesday named CVS Pharmacy, the retail division of CVS Health, the exclusive drug store for "Partner in Healthy Living," a new initiative with the nation's leading voluntary health organization to advancing the research, prevention, care and treatment of diabetes...

Featuring >> It's a common refrain in healthcare, heard among established companies and entrepreneurs alike, and among patients, providers, and payers: Despite massive investment,
no one has figured out how to change human behavior...

Featuring >> ViiV Healthcare wanted to nudge patients to start HIV drug treatment soon
after diagnosis. So the company recruited some experienced patients for “Couch Talk,” an educational program that offers some facts--and reassurance--about antiretroviral therapy...

Featuring >> Walgreens launched a new mental health platform and campaign to help
meet the growing need for resources and access to care...

Featuring >> According to an annual survey, consumers are searching more for treatment
options versus symptoms, paying attention to advertising and increasingly asking for specific
drugs by brand...

Featuring >> When Boehringer Ingelheim announced its 2015 financial results last week,
it spotlighted growth in multiple therapeutic areas. But diabetes, recently bolstered by
Jardiance and its cardiovascular risk-lowering data, stole the show...

Featuring >> Shire is looking for FDA approval of a new, chewable tablet of its popular
ADHD drug Vyvanse that is targeted to children and adolescents...

 

Featuring >> AstraZeneca hopes to raise awareness of the importance of an active lifestyle
in successful diabetes management through a new online initiative...

 

Featuring >> Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the
top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug...

 

Featuring >> The US FDA approved a trio of new drugs, namely Teva's Cinqair for asthma,
Eli Lilly's psoriasis drug Taltz and an anthrax therapy from Elusys...

 

Featuring >>  GlaxoSmithKline announced the official launch of its Children's Flonase
Allergy Relief. Available without a prescription, Children's Flonase is an over-the-counter
nasal spray approved to offer relief of allergy symptoms including runny nose, sneezing,
itchy nose, congestion and itchy, watery eyes...

 

Featuring >>  Allergan has already launched two DTC campaigns for its GI med Linzess.
In its third push, the company is putting patients front and center, highlighting individual
stories to tout the drug's advantages over OTC therapies...

 

 

Featuring >>  More drugs have come to mean more DTC advertising. And 2015 was a record
year for both. Pharma spent $5.17 billion on direct-to-consumer advertising last year, according
to Nielsen's calculations, nearing the previous pinnacle of $5.4 billion set in 2006. That's a 14.9% increase over the $4.5 billion spent in 2014, capping three years of DTC ad gains...

 

 

Featuring >>  The 20 drugs expected to top the worldwide ranks in 2020, as analyzed by the market research and consulting firm EvaluatePharma. They include some old standbys--Roche's Herceptin and Avastin, Pfizer and Amgen's Enbrel, Merck & Co.'s Januvia--and some brand-new entrants, such as Bristol-Myers Squibb's immuno-oncology treatment Opdivo, who hits the list in third place...

 

 

Featuring >>  Bug Spray Sales Up Double and Triple Digits; Target Moves Up Promotion Plans.
Most of the U.S. is months away from mosquito season, but growing concern about the
mosquito-borne Zika virus, found mainly in Latin America, is already leading to double- and
even triple-digit sales increases and stepped up merchandising for mosquito repellents...

 

 

Featuring >>  Merck & Co has filed a Biologics License Application in the US for its investigational, ALK-partnered* house dust mite pill. An approval in the US would broaden Merck’s offering of sublingual allergy immunotherapy (SLIT) tablets, adding to grass pollen allergy fill Grastek and Ragwitek for short ragweed pollen induced allergic rhinitis...

 

 

read more

Featuring >>  Avanir Pharmaceuticals announced Friday that the Food and Drug Administration had approved its new migraine treatment Onzetra Xsail (sumatriptan) nasal powder. The drug
is delivered via the Xsail breath-powered delivery device, allowing intranasal dosing of the most commonly prescribed migraine treatment...

 

 

Featuring >>  AbbVie and Roche scored priority review for their new leukemia therapy
venetoclax, putting the companies in line for a launch within 6 months. With analysts predicting 2020 sales of $2 billion--and both companies expecting biosimilar competition by 2018--
the med could be a welcome addition to their lineups...

 

 

read more

Week of January 19 Industry Highlights

Featuring >>  Look out, Merck & Co.: GlaxoSmithKline (GSK) expects its shingles candidate,
Shingrix, to be a "major market disrupter" when it wins approval. Glaxo is currently gearing
up to submit regulatory filings for Shingrix in North America, Japan and the EU, expected
for the second half of this year...

 

read more

Featuring >>  Shire agreed to buy Baxalta for $32 billion, creating the world's largest
rare-disease drugmaker. The deal will add Baxalta's hemophilia drugs to Shire's portfolio,
including Advate, which can cost between $200,000 to $500,000. The accepted offer
represents a 38% premium on Baxalta's share price...

 

 

read more

Featuring >>  Allergan and its partner Perrigo on Monday announced the launch of
combination guaifenesin 600mg and pseudoephedrine HCl 60mg extended-release
tablets to retail and wholesale customers. First shipments of this new store branded
product started in December and represents a first-to-market accomplishment for
Allergan and Perrigo...

 

read more

Week of January 4 Industry Highlights

Featuring >>  The FDA announced that it had approved the first seasonal influenza
vaccine to contain an adjuvant — an ingredient added to improve the body’s immune
response. Fluad, made by Novartis, is a trivalent vaccine intended for people aged 65
and older. It contains the adjuvant in MF59, an emulsion of squalene oil in water...

 

 

read more

Featuring >>  Respiratory drugs from Novartis and GlaxoSmithKline are top sellers
for their companies, with GSK's Advair a longtime megablockbuster. But along
with big sales, these drugs show more adverse events in post-marketing safety
data than competing products from Merck, according to a new report...

 

 

read more

Week of November 18 Industry Highlights

Featuring >>  Rite Aid and Harmonyx announced the availability of select genetic
tests in all Rite Aid pharmacies except those in New York. Rite Aid is the first U.S.
drugstore chain to offer Harmonyx genetic testing. The self-administered oral swab
test will help patients determine the effectiveness of their prescription medication
based on their genetic makeup...

 

 

read more

Week of November 13 Industry Highlights

Week of November 4 Industry Highlights

Featuring >> The neurology space is gearing up to shake free of its decade-long stagnancy,
with sector leaders and runners-up alike angling to push the boundaries. What that
means: Imminent advances in genetic sequencing, targeted treatments and diagnostics,
all designed to get to the biological root of neurological disorders...

 

 

read more

Featuring >> After a delay of more than two years, Novo Nordisk has at last been granted
approval in the US for Tresiba and Ryzodeg, two drugs expected to consolidate its position
as the leading diabetes company. Long-acting basal insulin Tresiba (insulin degludec)
and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able
to compete head-to-head in the market with Sanofi's $7bn-a-year blockbuster
Lantus (insulin glargine)...

 

 

read more

Week of October 19 Industry Highlights

Featuring >> Boehringer Ingelheim and Eli Lilly launched a DTC campaign for Jardiance
as they seek to differentiate the third-in-class type-2 diabetes drug in a competitive and
complex market. Lilly's Utke said a CRM program is expected to launch next week. The
DTC campaign's print and digital ads are targeted at health and lifestyle titles and there
are plans for digital display and mobile advertising...

 

 

read more

Week of October 12 Industry Highlights

Featuring >> Pfizer Consumer Healthcare announced the launch of Centrum VitaMints,
a multivitamin that offers consumers the essential nutrients they can enjoy like a mint.
Centrum VitaMints in Cool Mint flavor is intended for adults, and includes such nutrients
as Vitamins A, C, D and E. Serving size is two minty chewables daily which can be taken
with or without food or water...

 

 

read more

Week of september 28 Industry Highlights

Featuring >> Vertical will be the direct promotion partner to the OBGYN community
for Monistat and will detail OBGYN offices and clinics nationwide. This effort complements Prestige’s direct-to-consumer marketing of Monistat and further expands its professional
efforts. Doctors’ offices will be provided with patient education materials and Monistat
Sample & Savings packs...

 

 

read more

Week of september 21 Industry Highlights

Contact Us

Learn more about how our targeting solutions can help you reach a health- and wellness-focused audience.

For new career opportunities  >>

For the latest news in the healthcare
media and POC marketing space  >>

Our Address

Targeted Media Health
225 Liberty Street | New York, NY 10281